Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials

Transfusion

Volumn 36, Issue 2, 1996, Pages 175-186

  Vamvakas, E C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; META ANALYSIS; METHODOLOGY; MULTICENTER STUDY; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030064055     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.36296181932.x     Document Type: Article

References (84)

1. Gantt CL. Red blood cells for cancer patients (letter). Lancet 1981;2:363.
2. Van Aken WG. Does perioperative blood transfusion promote tumor growth? Transfus Med Rev 1989;3:243-52.
3. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994;118:371-9.
4. Tartter PI. Does blood transfusion predispose to cancer recurrence? Am J Clin Oncol 1989;12:169-72.
5. Francis DM. Relationship between blood transfusion and tumor behaviour. Br J Surg 1991;78:1420-8.
6. Vamvakas EC, Moore SB. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion 1993;33:754-65.
7. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion 1995;35:760-8.
8. Tartter PI. Blood transfusion and postoperative infections. Transfusion 1989;29:456-9.
9. Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994;34:714-27.
10. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253-9.
11. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987:30-53.
12. Miettinen O. Confounding and effect-modification. Am J Epidemiol 1974;100:350-3.
13. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982:242-80, 419-75.
14. Schlesselman JJ. Case-control studies: design, conduct, analysis. New York: Oxford University Press, 1982:227-90.
15. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. St. Louis: Mosby-Year Book, 1995.
16. Lilienfeld DE, Stolley PD. Foundations of epidemiology. New York: Oxford University Press, 1994:155-78.
17. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409-22.
18. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I. Medical. Stat Med 1989;8:441-54.
19. Miller JN, Colditz GA, Mosteller F. How study design affects outcomes in comparisons of therapy. II. Surgical. Stat Med 1989;8:455-66.
20. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-6.
21. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12:1859-67.
22. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993;342:1328-33.
23. Rosenberg SA, Seipp CA, White DE, et al. Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities. J Clin Oncol 1985;3:698-709.
24. Alexander JW. Transfusion-induced immunomodulation and infection (editorial). Transfusion 1991;31:195-6.
25. Waymack JP, Robb E, Alexander JW. Effect of transfusion on immune function in a traumatized animal model. II. Effect on mortality rate following septic challenge. Arch Surg 1987;122:935-9.
26. Waymack JP, Chance WT. Effect of blood transfusions on immune function. IV. Effect on tumor growth. J Surg Oncol 1988;39:159-64.
27. Lasek W, Plodziszewska M, Jakobisiak M. The effect of blood donation on natural killer activity in man. J Clin Lab Immunol 1987;22:165-8.
28. Marquet RL, Hoynck van Papendrecht MA, Busch OR, Jeekel J. Blood donation leads to a decrease in natural killer cell activity: a study in normal donors and cancer patients. Transfusion 1993;33:368-73
29. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science 1981;214:24-30.
30. Oldham RK. Natural killer cells: history, relevance, and clinical applications. Nat Immun Cell Growth Regul 1990;9:297-312.
31. Levy SM, Herberman RB, Lee J, et al. Persistently low natural killer cell activity, age, and environmental stress as predictors of infectious morbidity. Nat Immun Cell Growth Regul 1991;10:289-307.
32. Persijn GG, Cohen B, Lansbergen Q, van Rood JJ. Retrospective and prospective studies on the effect of blood transfusion in renal transplantation in The Netherlands. Transplantation 1979;28:396-401.
33. Rapaport FT, Dausset J. The possible role of leukocyte components in the production of beneficial effects of blood transfusion in human transplantation. Proceedings of the Ninth Congress of the Transplantation Society held August 23-27, 1982, at Brighton, UK. Transplant Proc 1983;15:952-5.
34. Lagaarj EL, Hennemann IP, Ruigrok M, et al. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989;321:701-5.
35. Van Twuyver E, Mooijaart RJ, ten Berge IJ, et al. Pretransplantation blood transfusion revisited. N Engl J Med 1991;325:1240-2.
36. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-8.
37. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79:513-6.
38. Heiss MM, Mempel W, Jauch KW, Schildberg FW. Leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer (letter). Lancet 1994;344:1429-30.
39. Pamphilon DH, ed. Modern transfusion medicine. Boca Raton, FL: CRC Press, 1995:107-23.
40. Blumberg N, Heal JM, Murphy P, et al. Association between transfusion of whole blood and recurrence of cancer. Br Med J (Clin Res Ed) 1986;293:530-3.
41. Marsh J, Donnan PT, Hamer-Hodges DW. Association between transfusion with plasma and the recurrence of colorectal carcinoma. Br J Surg 1990;77:623-6.
42. Keown PA, Descamps B. Improved renal allograft survival after blood transfusion: a nonspecific erythrocyte-mediated immunoregulatory process? Lancet 1979;1:20-2.
43. Shau H, Golub SH. Modulation of natural killer-mediated lysis by red blood cells. Cell Immunol 1988;116:60-72.
44. Busch OR, Hop WC, Marquet RL, Jeekel J. Autologous blood and infections after colorectal surgery (letter). Lancet 1994;343:668, discussion 668-9.
45. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-24.
46. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-8.
47. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979;242:2562-71.
48. Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34:483-6.
49. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-2.
50. Detre K, Peduzzi P. The problems of attributing deaths of nonadherers: the VA coronary bypass experience. Controlled Clin Trials 1982;3:355-64.
51. May GS, DeMets DL, Friedman LM, et al. The randomized clinical trial, bias in the analysis. Circulation 1981;64:669-73.
52. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
53. Halperin M, DeMets DL, Ware JH. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute. Stat Med 1990;9:881-92.
54. Houbiers JG, van de Watering LM, Verwey PJ, et al. Leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer (reply to letters). Lancet 1994;344:1430-1.
55. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
56. O'Gorman TW, Woolson RF, Jones MP. A comparison of two methods of estimating a common risk difference in a stratified analysis of a multicenter clinical trial. Controlled Clin Trials 1994;15:135-53.
57. Howard VJ, Grizzle J, Diener HC, et al. Comparison of multicenter study designs for investigation of carotid endarterectomy efficacy. Stroke 1992;23:583-93.
58. Fleiss JL. Multicentre clinical trials: Bradford Hill's contributions and some subsequent developments. Stat Med 1982;1:353-9.
59. Tabar L, Fagerberg CJG, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-33.
60. Appendix E: Algorithms for diagnosing infections. Special issue. The Centers for Disease Control SENIC Project (Study on Efficacy of Nosocomial Infection Control). Am J Epidemiol 1980;111:635-43.
61. McArdle CS, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 1991;302:1501-5.
62. Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
63. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
64. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-5.
65. Stampfer MJ, Goldhaber SZ, Yusuf S, et al. Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med 1982;307:1180-2.
66. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized controlled trial. Controlled Clin Trials 1981;2:31-49.
67. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
68. Blumberg N, Agarwal MM, Chuang C. Relation between recurrence of cancer of the colon and blood transfusion. Br Med J (Clin Res Ed) 1985;290:1037-9.
69. Voogt PJ, van de Velde CJ, Brand A, et al. Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987;59:836-43.
70. Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion 1991;31:212-7.
71. Busch OR, Hop WC, Marquet RL, Jeekel J. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg 1994;220:791-7.
72. Frankish PD, McNee RK, Alley PG, Woodfield DG. Relation between cancer of the colon and blood transfusion (letter). Br Med J (Clin Res Ed) 1985;290:1827.
73. Quintiliani L, Buzzonetti A, DiGirolamo M, et al. Effects of blood transfusion on the immune responsiveness and survival of cancer patients: a prospective study. Transfusion 1991;31:713-8.
74. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg 1992;216:633-8.
75. Sene A, Jeacock J, Robinson C, et al. Blood transfusion does not have an adverse effect on survival after operation for colorectal cancer. Ann R Coll Surg Engl 1993;75:261-7.
76. Sibbering DM, Locker AP, Hardcastle JD, Armitage NC. Blood transfusion and survival in colorectal cancer. Dis Colon Rectum 1994;37:358-63.
77. Kelsey JL, Thompson WD, Evans AS. Methods in observational epidemiology. New York: Oxford University Press, 1986.
78. Ness PM, Walsh PC, Zahurak M, et al. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood. Transfusion 1992;32:31-6.
79. Ford CD, VanMoorleghem G, Menlove RL. Blood transfusions and postoperative wound infection. Surgery 1993;113:603-7.
80. Craven DE, Kunches LM, Kilinsky V, et al. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986;133:792-6.
81. Meares EM Jr. Current patterns in nosocomial urinary tract infections. Urology 1991;37(Suppl 3):9-12.
82. Collignon PJ. Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis. Med J Aust 1994;161:374-8.
83. Blumberg N, Heal JM. Blood transfusions and prognosis in colorectal cancer (letter). N Engl J Med 1993;329:1355.
84. Mercuriali F, Gualtieri G, Sinigaglia L, et al. Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 1994;34:501-6.